Skip to main navigation Skip to search Skip to main content

Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias

  • S Cantilena
  • , L Gasparoli
  • , D Pal
  • , O Heidenreich
  • , JH Klusmann
  • , JHA Martens
  • , A Faille
  • , AJ Warren
  • , M Karsa
  • , R Pandher
  • , K Somers
  • , O Williams
  • , Boer J de*
  • *Corresponding author for this work

    Research output: Contribution to journal › Article (Academic Journal) › peer-review

    Abstract

    Background
    Improving the poor prognosis of infant leukaemias remains an unmet clinical need. This disease is a prototypical fusion oncoprotein-driven paediatric cancer, with MLL (KMT2A)-fusions present in most cases. Direct targeting of these driving oncoproteins represents a unique therapeutic opportunity. This rationale led us to initiate a drug screening with the aim of discovering drugs that can block MLL-fusion oncoproteins.

    Methods
    A screen for inhibition of MLL-fusion proteins was developed that overcomes the traditional limitations of targeting transcription factors. This luciferase reporter-based screen, together with a secondary western blot screen, was used to prioritize compounds. We characterized the lead compound, disulfiram (DSF), based on its efficient ablation of MLL-fusion proteins. The consequences of drug-induced MLL-fusion inhibition were confirmed by cell proliferation, colony formation, apoptosis assays, RT-qPCR, in vivo assays, RNA-seq and ChIP-qPCR and ChIP-seq analysis. All statistical tests were two-sided.

    Results
    Drug-induced inhibition of MLL-fusion proteins by DSF resulted in a specific block of colony formation in MLL-rearranged cells in vitro, induced differentiation and impeded leukaemia progression in vivo. Mechanistically, DSF abrogates MLL-fusion protein binding to DNA, resulting in epigenetic changes and down-regulation of leukaemic programmes setup by the MLL-fusion protein.

    Conclusion
    DSF can directly inhibit MLL-fusion proteins and demonstrate antitumour activity both in vitro and in vivo, providing, to our knowledge, the first evidence for a therapy that directly targets the initiating oncogenic MLL-fusion protein.
    Original languageEnglish
    Article numbere933
    Number of pages19
    JournalClinical and Translational Medicine
    Volume12
    Issue number6
    Early online date22 Jun 2022
    DOIs
    Publication statusPublished - Jun 2022

    Fingerprint

    Dive into the research topics of 'Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias'. Together they form a unique fingerprint.

    Cite this